Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase I/ Phase II Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 21, 2020
PEN-866 is the initial clinical program from Tarveda’s HSP90 binding miniature drug conjugate platform, designed to bind to activated Heat Shock Protein 90 (HSP90) in treating solid tumors.